Miltefosine in the treatment of cutaneous leishmaniasis caused by leishmania braziliensis in Brazil: A randomized and controlled trial

PLoS Neglected Tropical Diseases

Volumn 4, Issue 12, 2010, Pages 1-6

  Machado, Paulo R ^a   Ampuero, Julia ^b   Guimarães, Luiz H ^a   Villasboas, Leonardo ^a   Rocha, Ana T ^a   Schriefer, Albert ^a   Sousa, Rosana S ^a   Talhari, Anette ^c   Penna, Gerson ^b   Carvalho, Edgar M ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

^c FUNDAÇÃO DE MEDICINA TROPICAL DR HEITOR VIEIRA DOURADO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GENOMIC DNA; LIVER ENZYME; MEGLUMINE ANTIMONATE; MILTEFOSINE; POTASSIUM; SODIUM; UREA; ANTIMONY; ANTIPROTOZOAL AGENT; DRUG DERIVATIVE; PHOSPHORYLCHOLINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; BRAZIL; CHILD; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC PAIN; FEMALE; HUMAN; LEISHMANIA BRAZILIENSIS; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PARASITE IDENTIFICATION; POTASSIUM BLOOD LEVEL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RURAL AREA; SCHOOL CHILD; SIDE EFFECT; SKIN LEISHMANIASIS; SODIUM BLOOD LEVEL; TREATMENT DURATION; UREA BLOOD LEVEL; URTICARIA; VOMITING; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ISOLATION AND PURIFICATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PREVALENCE; TREATMENT OUTCOME;

ABDOMINAL PAIN; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIMONY; ANTIPROTOZOAL AGENTS; BRAZIL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS, CUTANEOUS; MALE; MIDDLE AGED; NAUSEA; PHOSPHORYLCHOLINE; PREVALENCE; TREATMENT OUTCOME; VOMITING; YOUNG ADULT;

EID: 78650696182     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000912     Document Type: Article

References (16)

1. Barral-Netto M, Machado P, Bittencourt A, Barral A (1997) Recent Advances in the Pathophysiology and Treatment of Human Cutaneous Leishmaniasis. Curr Op Dermatol 4: 51-58.
2. Jones TC, Johnson WDJ, Barretto AC, Lago E, Marsden PD (1987) Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis. J Infect Dis 156: 73-83.
3. Lessa MM, Lessa HA, Castro TW, Oliveira A, Scherifer A, et al. (2007) Mucosal leishmaniasis: epidemiological and clinical aspects. Braz J Otorhinolaryngol 73: 843-847.
4. Turetz M, Machado PRL, Ko A, Alves F, Bittencourt A, et al. (2002) Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. J Infect Dis 186: 1829-1834.
5. Romero GAS, Guerra MVF, Paes MG, Macêdo VO (2001) Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: Therapeutic response to meglumine antimonate. Am J Trop Med Hyg 65: 456-465.
6. O'Neal SE, Guimarães LH, Machado PR, Alcântara L, Morgan DJ, et al. (2007) Influence of helminth infections on the clinical course of and immune response to Leishmania braziliensis cutaneous leishmaniasis. J Infect Dis 195: 142-148.
7. Unger A, O'Neal S, Machado PR, Guimarães LH, Morgan D, et al. (2009) Association of Treatment of American Cutaneous Leishmaniasis Prior to Ulcer Development with High Rate of Failure in Northeastern Brazil. Am J Trop Med Hyg 80: 574-579.
8. Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, et al. (2006) Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J Infect Dis 193: 1375-1383.
9. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, et al. (2002) Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 1739-1746.
10. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, et al. (2004) Miltefosine for New World Cutaneous Leishmaniasis. Clin Infect Dis 38: 1266-1272.
11. Soto J, Rea J, Balderrama M, Toledo J, Soto P, et al. (2008) Short Report: Efficacy of Miltefosine for Bolivian Cutaneous Leishmaniasis. Am J Trop Med Hyg 78: 210-211.
12. Oliveira-Neto MP, Schubach A, Mattos M, Gonçalves-Costa SC, Pirmez C (1997) A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years). Am J Trop Med Hyg 57: 651-655.
13. Manual MS Ministério da Saúde, Fundação Nacional de Saúde, Centro Nacional de Epidemiologia (Brazil) (2007) Manual de Vigilância da Leishmaniose Tegumentar Americana, 2nd edition. Braśi{dotless}lia: Ministério da Saúde. Available at http://portal.saude.gov.br/portal/arquivos/pdf/manual_lta_2ed.pdf.
14. Schriefer A, Schriefer AL, Goes-Neto A, Guimaraes LH, Carvalho LP, et al. (2004) Multiclonal Leishmania braziliensis population structure and its clinical implication in a region of endemicity for American tegumentary leishmaniasis. Infect Immun 72: 508-514.
15. Arevalo J, Ramirez L, Adaui V, Zimic M, Tulliano G, et al. (2007) Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J Infect Dis 195: 1846-1851.
16. Guimarães LH, Machado PR, Lago EL, Morgan DJ, Schriefer A, et al. (2009) Atypical manifestations of tegumentary leishmaniasis in a transmission area of Leishmania braziliensis in the state of Bahia, Brazil. Trans R Soc Trop Med Hyg 103: 712-715.